Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xilio Therapeutics (XLO) Restructuring Costs (2024)

Xilio Therapeutics' Restructuring Costs history spans 1 years, with the latest figure at -$41000.0 for Q3 2024.

  • For Q3 2024, Restructuring Costs changed N/A year-over-year to -$41000.0; the TTM value through Dec 2024 reached $937000.0, changed N/A, while the annual FY2024 figure was $937000.0, N/A changed from the prior year.
  • Restructuring Costs for Q3 2024 was -$41000.0 at Xilio Therapeutics, down from $30000.0 in the prior quarter.
  • Across five years, Restructuring Costs topped out at $948000.0 in Q1 2024 and bottomed at -$41000.0 in Q3 2024.